< 生产厂家价格 >

甲磺酸卡莫司他

甲磺酸卡莫司他用途

Camostat (FOY305; FOY-S980)甲磺酸盐是胰蛋白酶样蛋白酶抑制剂。

点击显示

甲磺酸卡莫司他名称

[ CAS 号 ]:
59721-29-8

[ 中文名 ]:
甲磺酸卡莫司他

[ 英文名 ]:
Camostat Mesylate

[中文别名 ]:

[英文别名 ]:

Camostat Mesylate
MFCD00941410
Camostat mesilate
Camostat (mesylate)

甲磺酸卡莫司他生物活性

[ 描述 ]:

Camostat (FOY305; FOY-S980)甲磺酸盐是胰蛋白酶样蛋白酶抑制剂。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

[参考文献]

[1]. Okuno, M., et al., Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology, 2001. 120(7): p. 1784-800.

[2]. Yamamoto, A., et al., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res, 1994. 11(10): p. 1496-500.

[3]. Gibo, J., et al., Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest, 2005. 85(1): p. 75-89.

[相关活性小分子]

甲磺酸卡莫司他物理化学性质

[ 沸点 ]:
634.6ºC at 760 mmHg

[ 熔点 ]:
150-1550C

[ 分子式 ]:
C₂₁H₂₆N₄O₈S

[ 分子量 ]:
494.518

[ 精确质量 ]:
494.147125

[ PSA ]:
197.56000

[ LogP ]:
2.84290

[ 外观性状 ]:
结晶固体

[ 储存条件 ]:
Desiccate at RT

[ 水溶解性 ]:
水溶性：微溶；极微溶：乙醇；不溶：乙醚

甲磺酸卡莫司他毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CY1571620

CHEMICAL NAME :: Benzeneacetic acid, 4-((4-((aminoiminomethyl)amino)benzoyl)oxy)-, 2-(dimethylamino)-2- oxoethyl ester, monomethanesulfonate

CAS REGISTRY NUMBER :: 59721-29-8

LAST UPDATED :: 198708

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C20-H22-N4-O5.C-H4-O3-S

MOLECULAR WEIGHT :: 494.57

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 27,719,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1320 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 152 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 27,719,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985

点击显示

甲磺酸卡莫司他安全信息

[ 符号 ]:

GHS07, GHS09

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335-H400

[ 警示性声明 ]:
P261-P273-P305 + P351 + P338

[ 危害码 (欧洲) ]:
Xi,N

[ 风险声明 (欧洲) ]:
R36/37/38:Irritating to eyes, respiratory system and skin .

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
UN 3077 9 / PGIII

[ RTECS号 ]:
UV7720000

甲磺酸卡莫司他合成路线

详细合成路线

甲磺酸卡莫司他上下游产品

甲磺酸卡莫司他上游产品

甲磺酸卡莫司他下游产品

甲磺酸卡莫司他文献

ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.

Am. J. Physiol. Gastrointest. Liver Physiol. 307(7) , G700-10, (2014)

High levels of cholecystokinin (CCK) can stimulate pancreatic adaptive growth in which mature acinar cells divide, leading to enhanced pancreatic mass with parallel increases in protein, DNA, RNA, and...

Protease inhibitors targeting coronavirus and filovirus entry.

Antiviral Res. 116 , 76-84, (2015)

In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteas...

Correction of defective CFTR/ENaC function and tightness of cystic fibrosis airway epithelium by amniotic mesenchymal stromal (stem) cells.

J. Cell. Mol. Med. 18(8) , 1631-43, (2014)

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with most of the mortality given by the lung disease. Human amniotic mesenchymal stromal (stem) c...

更多文献